WO1999049017A3 - Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b - Google Patents

Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b Download PDF

Info

Publication number
WO1999049017A3
WO1999049017A3 PCT/US1999/006225 US9906225W WO9949017A3 WO 1999049017 A3 WO1999049017 A3 WO 1999049017A3 US 9906225 W US9906225 W US 9906225W WO 9949017 A3 WO9949017 A3 WO 9949017A3
Authority
WO
WIPO (PCT)
Prior art keywords
respiratory syncytial
virus
subgroup
attenuation
human respiratory
Prior art date
Application number
PCT/US1999/006225
Other languages
French (fr)
Other versions
WO1999049017A2 (en
Inventor
Stephen A Udem
Mohinderjit S Sidhu
Valerie B Randolph
Deborah A Buonagurio
Original Assignee
American Cyanamid Co
Stephen A Udem
Mohinderjit S Sidhu
Valerie B Randolph
Deborah A Buonagurio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co, Stephen A Udem, Mohinderjit S Sidhu, Valerie B Randolph, Deborah A Buonagurio filed Critical American Cyanamid Co
Priority to AU31095/99A priority Critical patent/AU767193B2/en
Priority to EP99912799A priority patent/EP1064358A2/en
Priority to JP2000537978A priority patent/JP2002507408A/en
Priority to IL13868199A priority patent/IL138681A0/en
Priority to CA002323927A priority patent/CA2323927A1/en
Priority to BR9909076-7A priority patent/BR9909076A/en
Priority to KR1020007010624A priority patent/KR20010080863A/en
Publication of WO1999049017A2 publication Critical patent/WO1999049017A2/en
Publication of WO1999049017A3 publication Critical patent/WO1999049017A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Isolated, recombinantly-generated, attenuated measles viruses and respiratory syncytial subgroup B viruses having defined attenuating mutations are described. Vaccines are formulated comprising such viruses and a physiologically acceptable carrier. The vaccines are used for immunizing an individual to induce protection against measles virus or respiratory syncytial subgroup B virus.
PCT/US1999/006225 1998-03-26 1999-03-22 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b WO1999049017A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU31095/99A AU767193B2 (en) 1998-03-26 1999-03-22 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup B
EP99912799A EP1064358A2 (en) 1998-03-26 1999-03-22 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
JP2000537978A JP2002507408A (en) 1998-03-26 1999-03-22 Mutations responsible for attenuation of measles virus or human respiratory syncytial virus subgroup B
IL13868199A IL138681A0 (en) 1998-03-26 1999-03-22 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
CA002323927A CA2323927A1 (en) 1998-03-26 1999-03-22 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
BR9909076-7A BR9909076A (en) 1998-03-26 1999-03-22 Attenuated measles virus, recombinantly generated, isolated, measles virus, human respiratory syncytial virus (rsv), subgroup b, attenuated, recombinantly generated, isolated, rsv, subgroup b, vaccine process for immunizing an individual to induce protection against virus measles, process for immunizing an individual to induce protection against rsv, subgroup b, composition, process for producing attenuated infectious measles virus, process for producing attenuated infectious rsv subgroup b
KR1020007010624A KR20010080863A (en) 1998-03-26 1999-03-22 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7946698P 1998-03-26 1998-03-26
US60/079,466 1998-03-26

Publications (2)

Publication Number Publication Date
WO1999049017A2 WO1999049017A2 (en) 1999-09-30
WO1999049017A3 true WO1999049017A3 (en) 1999-12-16

Family

ID=22150746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006225 WO1999049017A2 (en) 1998-03-26 1999-03-22 Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b

Country Status (9)

Country Link
EP (1) EP1064358A2 (en)
JP (1) JP2002507408A (en)
KR (1) KR20010080863A (en)
CN (2) CN1600852A (en)
AU (1) AU767193B2 (en)
BR (1) BR9909076A (en)
CA (1) CA2323927A1 (en)
IL (1) IL138681A0 (en)
WO (1) WO1999049017A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2273852T3 (en) * 2000-06-23 2007-05-16 Wyeth Holdings Corporation MODIFIED MORBILLIVIRUS PROTEINS V.
EP1375512B1 (en) * 2002-06-20 2009-07-22 Institut Pasteur Infectious cDNA of an approved vaccine strain of measles virus. Use for immunogenic compositions
US7572904B2 (en) 2003-03-28 2009-08-11 Medimmune, Llc Nucleic acids encoding respiratory syncytial virus subgroup B strain 9320
JPWO2008065752A1 (en) * 2006-11-30 2010-03-04 国立大学法人北海道大学 Immunotherapeutic drug containing diRNA
BRPI0921424A2 (en) 2008-11-05 2016-01-05 Merck Sharp & Dohme attenuated respiratory syncytial virus, immunogenic composition, nucleic acid molecule, recombinant cell, method for producing a protective immune response in a patient, and use of an immunologically effective amount of one or more of the following: an attenuated rsv, a population of rsv attenuated and an immunogenic composition.
EP2420242A1 (en) 2010-08-20 2012-02-22 Lauer, Ulrich M. Oncolytic measles virus
JP6453063B2 (en) * 2014-12-02 2019-01-16 国立大学法人北海道大学 Adjuvant composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540135A2 (en) * 1991-10-14 1993-05-05 The Kitasato Institute Attenuated measles vaccine virus strain containing specific nucleotide sequence and a method for its absolute identification
EP0567100A1 (en) * 1992-04-21 1993-10-27 American Cyanamid Company Mutant respiratory syncytial virus (RSV) vaccines containing same and methods of use
WO1998013501A2 (en) * 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0540135A2 (en) * 1991-10-14 1993-05-05 The Kitasato Institute Attenuated measles vaccine virus strain containing specific nucleotide sequence and a method for its absolute identification
EP0567100A1 (en) * 1992-04-21 1993-10-27 American Cyanamid Company Mutant respiratory syncytial virus (RSV) vaccines containing same and methods of use
WO1998013501A2 (en) * 1996-09-27 1998-04-02 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KURT P. TOLLEY ET AL: "Identification of mutations contributing to the reduced virukence of a modified strain of respiratory syncytial virus", VACCINE, vol. 14, no. 17/18, 1996, pages 1637 - 16461, XP004016825 *
TAKAYUKI MORI ET AL.: "Molecular cloning and complete nucleotide sequence of genomic RNA of the AIK-C strain of attenuated measles virus", VIRUS GENES, vol. 7, no. 1, 1993, pages 67 - 81, XP002051752 *

Also Published As

Publication number Publication date
CN1600852A (en) 2005-03-30
CA2323927A1 (en) 1999-09-30
CN1177927C (en) 2004-12-01
BR9909076A (en) 2000-12-05
IL138681A0 (en) 2001-10-31
WO1999049017A2 (en) 1999-09-30
JP2002507408A (en) 2002-03-12
AU767193B2 (en) 2003-11-06
KR20010080863A (en) 2001-08-25
EP1064358A2 (en) 2001-01-03
AU3109599A (en) 1999-10-18
CN1294628A (en) 2001-05-09

Similar Documents

Publication Publication Date Title
WO1998013501A3 (en) 3' genomic promoter region and polymerase gene mutations responsible for attenuation in viruses of the order designated mononegavirales
AU7501898A (en) Live attenuated virus vaccines for equine encephalitis viruses
WO2000002522A3 (en) Anthrax vaccine
AU3447497A (en) Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2
HUP9900389A3 (en) Mixture of recombinant viruses as polyenv vaccines for hiv, preparation and use thereof
AU2002254158A1 (en) Medical devices, compositions and methods for treating vulnerable plaque
HUP9903169A3 (en) Low pathogenicity prrs live virus vaccines and methods of preparation thereof
WO2000001409A3 (en) Porcine circovirus and parvovirus vaccine
WO1998013500A3 (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
ZA200202816B (en) Modified plant viruses and methods of use thereof.
AU2001263443A1 (en) F-protein epitope-based vaccine for respiratory syncytial virus infection
AU6882098A (en) Attenuated respiratory syncytial virus
WO1999049017A3 (en) Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
ZA964679B (en) Genetically altered feline immunodeficiency viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
AU3125795A (en) Attenuated human rotavirus vaccine
WO2004091524A3 (en) Respiratory virus vaccines
WO2001055111A8 (en) Biaryl compounds, their preparation and their use in therapy
EP1749885A3 (en) Infectious and attenuated bovine viral diarrhea virus clones; methods for their production and use
GB2332907B (en) EBV CTL Epitopes
EP0810283A3 (en) Live attenuated RTX-procucing bacteria of the family Pasteurellaceae
AU1386100A (en) Stable, attenuated rabies virus mutants and live vaccines thereof
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
WO2001064244A3 (en) In ovo protection against infectious bronchitis
AU4671701A (en) Medical compositions comprising (r,r)-formoterol and rofleponide
AU2438597A (en) Attenuated respiratory syncytial virus

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99804382.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999912799

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09646756

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/009256

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 537978

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2323927

Country of ref document: CA

Ref document number: 2323927

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 138681

Country of ref document: IL

Ref document number: 1020007010624

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 31095/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999912799

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007010624

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 31095/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999912799

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020007010624

Country of ref document: KR